Despite the clear need for peanut allergy treatments, as Peter discusses in this video, A-Immune’s FDA-approved desensitization therapy struggled commercially because patients feared potential anaphylaxis. As a result, investors remain cautious about backing similar approaches that expose patients to the allergen. The real opportunity lies in low-risk methods---ideally tackling multiple allergens---that can win over hesitant patients like the speaker’s daughter.